226 related articles for article (PubMed ID: 20237859)
1. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
Nowacek AS; McMillan J; Miller R; Anderson A; Rabinow B; Gendelman HE
J Neuroimmune Pharmacol; 2010 Dec; 5(4):592-601. PubMed ID: 20237859
[TBL] [Abstract][Full Text] [Related]
2. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
Nowacek AS; Balkundi S; McMillan J; Roy U; Martinez-Skinner A; Mosley RL; Kanmogne G; Kabanov AV; Bronich T; Gendelman HE
J Control Release; 2011 Mar; 150(2):204-11. PubMed ID: 21108978
[TBL] [Abstract][Full Text] [Related]
3. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections.
Puligujja P; McMillan J; Kendrick L; Li T; Balkundi S; Smith N; Veerubhotla RS; Edagwa BJ; Kabanov AV; Bronich T; Gendelman HE; Liu XM
Nanomedicine; 2013 Nov; 9(8):1263-73. PubMed ID: 23680933
[TBL] [Abstract][Full Text] [Related]
4. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.
Nowacek AS; Miller RL; McMillan J; Kanmogne G; Kanmogne M; Mosley RL; Ma Z; Graham S; Chaubal M; Werling J; Rabinow B; Dou H; Gendelman HE
Nanomedicine (Lond); 2009 Dec; 4(8):903-17. PubMed ID: 19958227
[TBL] [Abstract][Full Text] [Related]
5. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
Balkundi S; Nowacek AS; Veerubhotla RS; Chen H; Martinez-Skinner A; Roy U; Mosley RL; Kanmogne G; Liu X; Kabanov AV; Bronich T; McMillan J; Gendelman HE
Int J Nanomedicine; 2011; 6():3393-404. PubMed ID: 22267924
[TBL] [Abstract][Full Text] [Related]
6. Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages.
Araínga M; Guo D; Wiederin J; Ciborowski P; McMillan J; Gendelman HE
Retrovirology; 2015 Jan; 12():5. PubMed ID: 25608975
[TBL] [Abstract][Full Text] [Related]
7. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.
Gautam N; Roy U; Balkundi S; Puligujja P; Guo D; Smith N; Liu XM; Lamberty B; Morsey B; Fox HS; McMillan J; Gendelman HE; Alnouti Y
Antimicrob Agents Chemother; 2013 Jul; 57(7):3110-20. PubMed ID: 23612193
[TBL] [Abstract][Full Text] [Related]
9. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.
Dash PK; Gendelman HE; Roy U; Balkundi S; Alnouti Y; Mosley RL; Gelbard HA; McMillan J; Gorantla S; Poluektova LY
AIDS; 2012 Nov; 26(17):2135-44. PubMed ID: 22824628
[TBL] [Abstract][Full Text] [Related]
10. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.
Guo D; Zhang G; Wysocki TA; Wysocki BJ; Gelbard HA; Liu XM; McMillan JM; Gendelman HE
J Virol; 2014 Sep; 88(17):9504-13. PubMed ID: 24920821
[TBL] [Abstract][Full Text] [Related]
11. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.
Kanmogne GD; Singh S; Roy U; Liu X; McMillan J; Gorantla S; Balkundi S; Smith N; Alnouti Y; Gautam N; Zhou Y; Poluektova L; Kabanov A; Bronich T; Gendelman HE
Int J Nanomedicine; 2012; 7():2373-88. PubMed ID: 22661891
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
King JR; Yogev R; Jean-Philippe P; Graham B; Wiznia A; Britto P; Carey V; Hazra R; Acosta EP;
Antimicrob Agents Chemother; 2011 Sep; 55(9):4290-4. PubMed ID: 21670182
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
Scarsi KK; Cramer YS; Rosenkranz SL; Aweeka F; Berzins B; Coombs RW; Coughlin K; Moran LE; Zorrilla CD; Akelo V; Aziz M; Friedman RK; Gingrich D; Swaminathan S; Godfrey C; Cohn SE;
Lancet HIV; 2019 Sep; 6(9):e601-e612. PubMed ID: 31498109
[TBL] [Abstract][Full Text] [Related]
14. Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.
Martinez-Skinner AL; Veerubhotla RS; Liu H; Xiong H; Yu F; McMillan JM; Gendelman HE
J Proteome Res; 2013 May; 12(5):2282-94. PubMed ID: 23544708
[TBL] [Abstract][Full Text] [Related]
15. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
[TBL] [Abstract][Full Text] [Related]
16. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.
Huang J; Gautam N; Bathena SP; Roy U; McMillan J; Gendelman HE; Alnouti Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2332-8. PubMed ID: 21752731
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
19. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Daar ES; Tierney C; Fischl MA; Sax PE; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Pappa KA; Woodward WC; Patterson K; Bolivar H; Benson CA; Collier AC;
Ann Intern Med; 2011 Apr; 154(7):445-56. PubMed ID: 21320923
[TBL] [Abstract][Full Text] [Related]
20. [A single tablet against HIV: new combination preparation improves therapy].
Pommer P
Dtsch Med Wochenschr; 2012 Aug; 137(34-35):1673. PubMed ID: 22893044
[No Abstract] [Full Text] [Related]
[Next] [New Search]
